A unique case of chronic myeloid leukemia presenting as monocular vision loss with unilateral retinopathy.

BCR-ABL1 Chronic myeloid leukemia Hasford Imatinib Monocular vision loss Sokal Unilateral retinopathy

Journal

American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 18 07 2018
revised: 08 11 2018
accepted: 06 02 2019
entrez: 27 3 2019
pubmed: 27 3 2019
medline: 27 3 2019
Statut: epublish

Résumé

To report a case of unilateral leukemic retinopathy secondary to chronic myeloid leukemia (CML). Patient presented to clinic with a visual acuity (VA) of 20/200 in the right eye (OD) after several months of progressive monocular vision loss and was found to have dense pre-retinal hemorrhage. Patient underwent 23-gauge pars plana vitrectomy to clear the preretinal hemorrhage along with a complex macula-off retinal detachment repair to address retinal tear and multilayer retinal hemorrhage. The patient was subsequently diagnosed with CML as she was found to be positive for the fusion protein of break point cluster gene (BCR) with Abelson tyrosine kinase (ABL1), BCR-ABL1, upon systemic work-up. Imatinib therapy resulted in complete hematologic and cytogenetic resolution after one month, however, the patient's vision remained unchanged six months after surgery. To the authors' knowledge, this is the first reported case of unilateral leukemic retinopathy secondary to low risk CML, as determined by the Sokal and Hasford prognostic scoring systems. CML should be included in the differential diagnosis of patients with progressive monocular vision loss with suspicious multi-layer retinal compromise.

Identifiants

pubmed: 30911698
doi: 10.1016/j.ajoc.2019.02.003
pii: S2451-9936(18)30238-X
pmc: PMC6416657
doi:

Types de publication

Case Reports

Langues

eng

Pagination

67-69

Références

Br J Ophthalmol. 1992 Nov;76(11):651-5
pubmed: 1477038
Coll Antropol. 2005;29 Suppl 1:141-3
pubmed: 16193698
Curr Cancer Drug Targets. 2011 Jan;11(1):3-19
pubmed: 21062244
Middle East Afr J Ophthalmol. 2011 Oct;18(4):336-8
pubmed: 22224030
J AAPOS. 2012 Aug;16(4):406-8
pubmed: 22929456
Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):353-6
pubmed: 24339689
Can J Ophthalmol. 2014 Jun;49(3):e68-70
pubmed: 24862787
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94
pubmed: 27101984
Retina. 2018 Jan;38(1):137-147
pubmed: 28099315
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Ophthalmology. 1983 Aug;90(8):899-905
pubmed: 6195573
Surv Ophthalmol. 1983 Jan-Feb;27(4):211-32
pubmed: 6342189
Blood. 1984 Apr;63(4):789-99
pubmed: 6584184
J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
pubmed: 9625174

Auteurs

Mark P Seraly (MP)

West Virginia University School of Medicine, 1 Medical Center Dr, Morgantown, WV, USA.

Sumeet K Gupta (SK)

West Virginia University School of Medicine, 1 Medical Center Dr, Morgantown, WV, USA.

Inderjit Mehmi (I)

West Virginia University School of Medicine, 1 Medical Center Dr, Morgantown, WV, USA.
West Virginia University Cancer Institute, Section of Hematology/Oncology, 1 Medical Center Dr, Morgantown, WV, USA.

Lauren Veltri (L)

West Virginia University School of Medicine, 1 Medical Center Dr, Morgantown, WV, USA.
West Virginia University Cancer Institute, Section of Hematology/Oncology, 1 Medical Center Dr, Morgantown, WV, USA.

Ghassan R Ghorayeb (GR)

West Virginia University School of Medicine, 1 Medical Center Dr, Morgantown, WV, USA.

Classifications MeSH